Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma

被引:9
|
作者
Yamashita, Suguru [1 ]
Overman, Michael J. [2 ]
Wang, Huamin [3 ]
Zhao, Jun [3 ]
Okuno, Masayuki [1 ]
Goumard, Claire [1 ]
Tzeng, Ching-Wei [1 ]
Kim, Michael [1 ]
Fleming, Jason B. [1 ]
Vauthey, Jean-Nicolas [1 ]
Katz, Matthew H. [1 ]
Lee, Jeffrey E. [1 ]
Conrad, Claudius [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
PANCREATIC DUCTAL ADENOCARCINOMA; COLORECTAL LIVER METASTASES; PHASE-II; FRACTIONATED CHEMORADIATION; NEOADJUVANT CHEMORADIATION; TRACT CANCER; VATER; CHEMOTHERAPY; GEMCITABINE; CARCINOMA;
D O I
10.1245/s10434-017-6098-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established. Methods. A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (>= 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS). Results. For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS. Conclusion. The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
引用
收藏
页码:3954 / 3963
页数:10
相关论文
共 50 条
  • [1] Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma
    Suguru Yamashita
    Michael J. Overman
    Huamin Wang
    Jun Zhao
    Masayuki Okuno
    Claire Goumard
    Ching-Wei Tzeng
    Michael Kim
    Jason B. Fleming
    Jean-Nicolas Vauthey
    Matthew H. Katz
    Jeffrey E. Lee
    Claudius Conrad
    Annals of Surgical Oncology, 2017, 24 : 3954 - 3963
  • [2] Pathologic Subtypes of Ampullary Adenocarcinoma: Value of Ampullary MDCT for Noninvasive Preoperative Differentiation
    Ivanovic, Aleksandar M.
    Alessandrino, Francesco
    Maksimovic, Ruzica
    Micev, Marjan
    Ostojic, Slavenko
    Gore, Richard M.
    Mortele, Koenraad J.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 208 (03) : W71 - W78
  • [3] Defining the Role of Adjuvant Therapy: Ampullary and Duodenal Adenocarcinoma
    Jabbour, Selma K.
    Mulvihill, David
    SEMINARS IN RADIATION ONCOLOGY, 2014, 24 (02) : 85 - 93
  • [4] Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review
    Chunmeng Zhang
    Jason M. Lizalek
    Collin Dougherty
    Danielle M. Westmark
    Kelsey A. Klute
    Bradley N. Reames
    Annals of Surgical Oncology, 2024, 31 : 792 - 803
  • [5] Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review
    Zhang, Chunmeng
    Lizalek, Jason M.
    Dougherty, Collin
    Westmark, Danielle M.
    Klute, Kelsey A.
    Reames, Bradley N.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (02) : 1347 - 1357
  • [6] Extra-ampullary Duodenal Adenocarcinoma
    Ushiku, Tetsuo
    Arnason, Thomas
    Fukayama, Masashi
    Lauwers, Gregory Y.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (11) : 1484 - 1493
  • [7] Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma
    Cloyd, Jordan M.
    Wang, Huamin
    Egger, Michael E.
    Tzeng, Ching-Wei D.
    Prakash, Laura R.
    Maitra, Anirban
    Varadhachary, Gauri R.
    Shroff, Rachna
    Javle, Milind
    Fogelman, David
    Wolff, Robert A.
    Overman, Michael J.
    Koay, Eugene J.
    Das, Prajnan
    Herman, Joseph M.
    Kim, Michael P.
    Vauthey, Jean-Nicolas
    Aloia, Thomas A.
    Fleming, Jason B.
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    JAMA SURGERY, 2017, 152 (11) : 1048 - 1056
  • [8] Comparative analysis of resected duodenal and ampullary adenocarcinoma.
    Crown, Angelena
    Edwards, Alicia M.
    Rocha, Flavio G.
    Picozzi, Vincent J.
    Helton, Scott
    Biehl, Thomas R.
    Alseidi, Adnan
    Lin, Bruce S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Prognostic factors of non-ampullary duodenal adenocarcinoma
    Hirashita, Teijiro
    Ohta, Masayuki
    Tada, Kazuhiro
    Saga, Kunihiro
    Takayama, Hiroomi
    Endo, Yuichi
    Uchida, Hiroki
    Iwashita, Yukio
    Inomata, Masafumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (08) : 743 - 747
  • [10] Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma
    Fields, R. C.
    Strong, V. E.
    Goenen, M.
    Goodman, K. A.
    Rizk, N. P.
    Kelsen, D. P.
    Ilson, D. H.
    Tang, L. H.
    Brennan, M. F.
    Coit, D. G.
    Shah, M. A.
    BRITISH JOURNAL OF CANCER, 2011, 104 (12) : 1840 - 1847